Visualization, Data Extraction, and Multiparametric Analysis of 3D Pancreatic and Colorectal Cancer Cell Lines for High-Throughput Screening
Abstract
1. Introduction
2. Materials and Methods
2.1. Cell Lines and Culture Conditions
2.2. Data Collection for Spheroid Analysis Under Cytostatic Exposure
2.3. Data Analysis
2.4. Mathematical Framework for Multiparametric Analysis
- Normalization of extracted features to the [0, 1] range on control values:
- 2.
- Feature transformation by conditional 1/x inversion for parameters that show reverse trends:
- 3.
- PCA for feature weighting: Components were selected to explain ≥90% of variance. The weight for each feature j was computed as follows:
- 4.
- Computation of the final weighted metric:
3. Results and Discussion
3.1. Proliferation Analysis of Spheroids
- Outlier identification from raw data:
- If, after removal of one value, the standard deviation in a triplicate exceeded 20%, the point was excluded from analysis [55].
- If an outlier was present within the IC50 range or the inflection point of the logarithmic curve, the graph was considered invalid [56].
- A single exclusion was allowed while preserving the inhibition profile, provided that the outlier was located within the plateau region.
- Outlier reproducibility and data loss evaluation: If outliers were systemic and resulted in repeated failures of plates or inconsistency in graphs, the cell line was considered “problematic”. In such cases, a large number of outliers can increase the CV to more than 20%, and the plate values will fail the acceptable threshold without total data loss [42,49].
- In fact, due to the data collected, the LoVo cell line was highlighted as problematic. Figure 1B shows that after preprocessing, the coefficient of variation was very high, with outliers reaching over 20%. For such cases, the refined analysis developed in the current paper can be of special value.
3.2. Optimization of Optical Analysis Conditions and Data Extraction in CellProfiler
- Area Shape;
- Compactness;
- Form Factor;
- Median Radius;
- Perimeter;
- Solidity;
- Granularity–iterations, in which the signal change exceeded 5%.
3.3. Multiparametric Analysis of Morphological Features of Spheroids Using a New Metric
- Extract all data from the final CSV file into an Excel-friendly format, showing values in positions corresponding to the well plate layout;
- Check all studied metrics for outliers using the Q-test (Dixon’s test) in triplicate. Since the coefficient of variation is sensitive to data scale and metrics can be very different in range, such as area shape within hundreds of thousands, while form factor is in single digits, certain adjustments had to be made accordingly [53,54];
- Normalize obtained features to a unified scale.
- Verify and transform features using the inversion x−1 method. If a feature’s mean value in a triplicate exceeded 1 after normalization, it indicated an increase in titration relative to the control. Since different features could trend differently with concentration, direct aggregation without transformation could misrepresent compound effects [43,62,63].
- Re-check the transformed features and reverse them if needed. In cases where the mean feature value rose after transformation, this signaled that either the original data remained constant or had just slightly decreased and should return to its initial value.
- Perform PCA to find the weights of the studied metrics. Giving feature weights manually would be problematic, as well as subjective, since different cell lines have different important features. The PCA enabled us to reduce the dimensionality and compute weight coefficients based on the explained variance, which is illustrated in Figure 4 and Figure 5 [40]. As there is no clearly accepted criterion for selecting the exact number of principal components in analysis [64,65], we adopted a cumulative explained variance threshold of 90%, following commonly used approaches in multiparametric and image-based PCA studies [66,67,68,69]. Feature weights were computed based on this.
- Finally, the script developed a comparative value per well by summing weighted feature scores, normalizing the total sum to 1, and generating the final weighted values corresponding to each metric.
3.4. Validation of the PCA-Based Feature Weighting Algorithm
4. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Attene-Ramos, M.S.; Austin, C.P.; Xia, M. High Throughput Screening. In Encyclopedia of Toxicology; Elsevier: Amsterdam, The Netherlands, 2014; pp. 916–917. ISBN 978-0-12-386455-0. [Google Scholar]
- Szymański, P.; Markowicz, M.; Mikiciuk-Olasik, E. Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests. IJMS 2011, 13, 427–452. [Google Scholar] [CrossRef]
- Law, A.M.K.; Rodriguez De La Fuente, L.; Grundy, T.J.; Fang, G.; Valdes-Mora, F.; Gallego-Ortega, D. Advancements in 3D Cell Culture Systems for Personalizing Anti-Cancer Therapies. Front. Oncol. 2021, 11, 782766. [Google Scholar] [CrossRef] [PubMed]
- Ock, J.; Li, W. A High-Throughput Three-Dimensional Cell Culture Platform for Drug Screening. Bio-Des. Manuf. 2020, 3, 40–47. [Google Scholar] [CrossRef]
- Parasrampuria, D.A.; Benet, L.Z.; Sharma, A. Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations. AAPS J. 2018, 20, 46. [Google Scholar] [CrossRef]
- Wang, Y.; Jeon, H. 3D Cell Cultures Toward Quantitative High-Throughput Drug Screening. Trends Pharmacol. Sci. 2022, 43, 569–581. [Google Scholar] [CrossRef]
- Lv, D.; Hu, Z.; Lu, L.; Lu, H.; Xu, X. Three-dimensional Cell Culture: A Powerful Tool in Tumor Research and Drug Discovery (Review). Oncol. Lett. 2017, 14, 6999–7010. [Google Scholar] [CrossRef]
- Mehta, G.; Hsiao, A.Y.; Ingram, M.; Luker, G.D.; Takayama, S. Opportunities and Challenges for Use of Tumor Spheroids as Models to Test Drug Delivery and Efficacy. J. Control. Release 2012, 164, 192–204. [Google Scholar] [CrossRef] [PubMed]
- Costa, E.C.; Moreira, A.F.; de Melo-Diogo, D.; Gaspar, V.M.; Carvalho, M.P.; Correia, I.J. 3D Tumor Spheroids: An Overview on the Tools and Techniques Used for Their Analysis. Biotechnol. Adv. 2016, 34, 1427–1441. [Google Scholar] [CrossRef] [PubMed]
- Benien, P.; Swami, A. 3D Tumor Models: History, Advances and Future Perspectives. Future Oncol. 2014, 10, 1311–1327. [Google Scholar] [CrossRef]
- Edmondson, R.; Broglie, J.J.; Adcock, A.F.; Yang, L. Three-Dimensional Cell Culture Systems and Their Applications in Drug Discovery and Cell-Based Biosensors. Assay Drug Dev. Technol. 2014, 12, 207–218. [Google Scholar] [CrossRef]
- Montanez-Sauri, S.I.; Sung, K.E.; Berthier, E.; Beebe, D.J. Enabling Screening in 3D Microenvironments: Probing Matrix and Stromal Effects on the Morphology and Proliferation of T47D Breast Carcinoma Cells. Integr. Biol. 2013, 5, 631–640. [Google Scholar] [CrossRef]
- Rimann, M.; Graf-Hausner, U. Synthetic 3D Multicellular Systems for Drug Development. Curr. Opin. Biotechnol. 2012, 23, 803–809. [Google Scholar] [CrossRef]
- Ryan, S.-L.; Baird, A.-M.; Vaz, G.; Urquhart, A.J.; Senge, M.; Richard, D.J.; O’Byrne, K.J.; Davies, A.M. Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture. Assay Drug Dev. Technol. 2016, 14, 19–28. [Google Scholar] [CrossRef]
- Janzen, W.P. Screening Technologies for Small Molecule Discovery: The State of the Art. Chem. Biol. 2014, 21, 1162–1170. [Google Scholar] [CrossRef]
- Wang, H.; Brown, P.C.; Chow, E.C.Y.; Ewart, L.; Ferguson, S.S.; Fitzpatrick, S.; Freedman, B.S.; Guo, G.L.; Hedrich, W.; Heyward, S.; et al. 3D Cell Culture Models: Drug Pharmacokinetics, Safety Assessment, and Regulatory Consideration. Clin. Transl. Sci. 2021, 14, 1659–1680. [Google Scholar] [CrossRef] [PubMed]
- Nath, S.; Devi, G.R. Three-Dimensional Culture Systems in Cancer Research: Focus on Tumor Spheroid Model. Pharmacol. Ther. 2016, 163, 94–108. [Google Scholar] [CrossRef] [PubMed]
- Carragher, N.; Piccinini, F.; Tesei, A.; Trask, O.J., Jr.; Bickle, M.; Horvath, P. Concerns, Challenges and Promises of High-Content Analysis of 3D Cellular Models. Nat. Rev. Drug Discov. 2018, 17, 606. [Google Scholar] [CrossRef] [PubMed]
- Hiramoto, K.; Ino, K.; Komatsu, K.; Nashimoto, Y.; Shiku, H. Electrochemiluminescence Imaging of Respiratory Activity of Cellular Spheroids Using Sequential Potential Steps. Biosens. Bioelectron. 2021, 181, 113123. [Google Scholar] [CrossRef]
- Rios, A.C.; Clevers, H. Imaging Organoids: A Bright Future Ahead. Nat. Methods 2018, 15, 24–26. [Google Scholar] [CrossRef]
- Hiemstra, S.; Ramaiahgari, S.C.; Wink, S.; Callegaro, G.; Coonen, M.; Meerman, J.; Jennen, D.; van den Nieuwendijk, K.; Dankers, A.; Snoeys, J.; et al. High-Throughput Confocal Imaging of Differentiated 3D Liver-like Spheroid Cellular Stress Response Reporters for Identification of Drug-Induced Liver Injury Liability. Arch. Toxicol. 2019, 93, 2895–2911. [Google Scholar] [CrossRef]
- Antunes, J.; Gaspar, V.M.; Ferreira, L.; Monteiro, M.; Henrique, R.; Jerónimo, C.; Mano, J.F. In-Air Production of 3D Co-Culture Tumor Spheroid Hydrogels for Expedited Drug Screening. Acta Biomater. 2019, 94, 392–409. [Google Scholar] [CrossRef]
- Fang, G.; Lu, H.; Rodriguez De La Fuente, L.; Law, A.M.K.; Lin, G.; Jin, D.; Gallego-Ortega, D. Mammary Tumor Organoid Culture in Non-Adhesive Alginate for Luminal Mechanics and High-Throughput Drug Screening. Adv. Sci. 2021, 8, 2102418. [Google Scholar] [CrossRef]
- Hale, L.J.; Howden, S.E.; Phipson, B.; Lonsdale, A.; Er, P.X.; Ghobrial, I.; Hosawi, S.; Wilson, S.; Lawlor, K.T.; Khan, S.; et al. 3D Organoid-Derived Human Glomeruli for Personalised Podocyte Disease Modelling and Drug Screening. Nat. Commun. 2018, 9, 5167. [Google Scholar] [CrossRef]
- Tam, R.Y.; Yockell-Lelièvre, J.; Smith, L.J.; Julian, L.M.; Baker, A.E.G.; Choey, C.; Hasim, M.S.; Dimitroulakos, J.; Stanford, W.L.; Shoichet, M.S. Rationally Designed 3D Hydrogels Model Invasive Lung Diseases Enabling High-Content Drug Screening. Adv. Mater. 2019, 31, 1806214. [Google Scholar] [CrossRef] [PubMed]
- Choo, N.; Ramm, S.; Luu, J.; Winter, J.M.; Selth, L.A.; Dwyer, A.R.; Frydenberg, M.; Grummet, J.; Sandhu, S.; Hickey, T.E.; et al. High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. SLAS Discov. 2021, 26, 1107–1124. [Google Scholar] [CrossRef] [PubMed]
- Danovi, D.; Folarin, A.; Gogolok, S.; Ender, C.; Elbatsh, A.M.O.; Engström, P.G.; Stricker, S.H.; Gagrica, S.; Georgian, A.; Yu, D.; et al. A High-Content Small Molecule Screen Identifies Sensitivity of Glioblastoma Stem Cells to Inhibition of Polo-Like Kinase 1. PLoS ONE 2013, 8, e77053. [Google Scholar] [CrossRef]
- Mattiazzi Usaj, M.; Styles, E.B.; Verster, A.J.; Friesen, H.; Boone, C.; Andrews, B.J. High-Content Screening for Quantitative Cell Biology. Trends Cell Biol. 2016, 26, 598–611. [Google Scholar] [CrossRef] [PubMed]
- Boussaad, I.; Cruciani, G.; Bolognin, S.; Antony, P.; Dording, C.M.; Kwon, Y.-J.; Heutink, P.; Fava, E.; Schwamborn, J.C.; Krüger, R. Integrated, Automated Maintenance, Expansion and Differentiation of 2D and 3D Patient-Derived Cellular Models for High Throughput Drug Screening. Sci. Rep. 2021, 11, 1439. [Google Scholar] [CrossRef]
- Carpenter, A.E.; Jones, T.R.; Lamprecht, M.R.; Clarke, C.; Kang, I.H.; Friman, O.; Guertin, D.A.; Chang, J.H.; Lindquist, R.A.; Moffat, J.; et al. CellProfiler: Image Analysis Software for Identifying and Quantifying Cell Phenotypes. Genome Biol. 2006, 7, R100. [Google Scholar] [CrossRef]
- Kamentsky, L.; Jones, T.R.; Fraser, A.; Bray, M.-A.; Logan, D.J.; Madden, K.L.; Ljosa, V.; Rueden, C.; Eliceiri, K.W.; Carpenter, A.E. Improved Structure, Function and Compatibility for CellProfiler: Modular High-Throughput Image Analysis Software. Bioinformatics 2011, 27, 1179–1180. [Google Scholar] [CrossRef]
- McQuin, C.; Goodman, A.; Chernyshev, V.; Kamentsky, L.; Cimini, B.A.; Karhohs, K.W.; Doan, M.; Ding, L.; Rafelski, S.M.; Thirstrup, D.; et al. CellProfiler 3.0: Next-Generation Image Processing for Biology. PLoS Biol. 2018, 16, e2005970. [Google Scholar] [CrossRef] [PubMed]
- Bray, M.-A.; Singh, S.; Han, H.; Davis, C.T.; Borgeson, B.; Hartland, C.; Kost-Alimova, M.; Gustafsdottir, S.M.; Gibson, C.C.; Carpenter, A.E. Cell Painting, a High-Content Image-Based Assay for Morphological Profiling Using Multiplexed Fluorescent Dyes. Nat. Protoc. 2016, 11, 1757–1774. [Google Scholar] [CrossRef]
- Cimini, B.A.; Chandrasekaran, S.N.; Kost-Alimova, M.; Miller, L.; Goodale, A.; Fritchman, B.; Byrne, P.; Garg, S.; Jamali, N.; Logan, D.J.; et al. Optimizing the Cell Painting Assay for Image-Based Profiling. Nat. Protoc. 2023, 18, 1981–2013. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Fossa, F.; Cruz, M.C.; Haghighi, M.; de Jesus, M.B.; Singh, S.; Carpenter, A.E.; Cimini, B.A. Interpreting Image-Based Profiles Using Similarity Clustering and Single-Cell Visualization. Curr. Protoc. 2023, 3, e713. [Google Scholar] [CrossRef]
- Caicedo, J.C.; Arevalo, J.; Piccioni, F.; Bray, M.-A.; Hartland, C.L.; Wu, X.; Brooks, A.N.; Berger, A.H.; Boehm, J.S.; Carpenter, A.E.; et al. Cell Painting Predicts Impact of Lung Cancer Variants. Mol. Biol. Cell 2022, 33, ar49. [Google Scholar] [CrossRef] [PubMed]
- Lazzari, G.; Nicolas, V.; Matsusaki, M.; Akashi, M.; Couvreur, P.; Mura, S. Multicellular Spheroid Based on a Triple Co-Culture: A Novel 3D Model to Mimic Pancreatic Tumor Complexity. Acta Biomater. 2018, 78, 296–307. [Google Scholar] [CrossRef]
- Alsehli, H.; Mosis, F.; Thompson, C.; Hamrud, E.; Wiseman, E.; Gentleman, E.; Danovi, D. An Integrated Pipeline for High-Throughput Screening and Profiling of Spheroids Using Simple Live Image Analysis of Frame to Frame Variations. Methods 2021, 190, 33–43. [Google Scholar] [CrossRef]
- Aguilar Cosme, J.R.; Gagui, D.C.; Bryant, H.E.; Claeyssens, F. Morphological Response in Cancer Spheroids for Screening Photodynamic Therapy Parameters. Front. Mol. Biosci. 2021, 8, 784962. [Google Scholar] [CrossRef]
- Jolliffe, I.T.; Cadima, J. Principal Component Analysis: A Review and Recent Developments. Phil. Trans. R. Soc. A 2016, 374, 20150202. [Google Scholar] [CrossRef]
- Ringnér, M. What Is Principal Component Analysis? Nat. Biotechnol. 2008, 26, 303–304. [Google Scholar] [CrossRef] [PubMed]
- Zanoni, M.; Piccinini, F.; Arienti, C.; Zamagni, A.; Santi, S.; Polico, R.; Bevilacqua, A.; Tesei, A. 3D Tumor Spheroid Models for In Vitro Therapeutic Screening: A Systematic Approach to Enhance the Biological Relevance of Data Obtained. Sci. Rep. 2016, 6, 19103. [Google Scholar] [CrossRef] [PubMed]
- Caicedo, J.C.; Cooper, S.; Heigwer, F.; Warchal, S.; Qiu, P.; Molnar, C.; Vasilevich, A.S.; Barry, J.D.; Bansal, H.S.; Kraus, O.; et al. Data-Analysis Strategies for Image-Based Cell Profiling. Nat. Methods 2017, 14, 849–863. [Google Scholar] [CrossRef]
- Ringers, C.; Holmberg, D.; Flobak, Å.; Georgieva, P.; Jarvius, M.; Johansson, M.; Larsson, A.; Rosén, D.; Seashore–Ludlow, B.; Visnes, T.; et al. High-Content Morphological Profiling by Cell Painting in 3D Spheroids. bioRxiv 2025. [Google Scholar] [CrossRef]
- Luca, A.C.; Mersch, S.; Deenen, R.; Schmidt, S.; Messner, I.; Schäfer, K.-L.; Baldus, S.E.; Huckenbeck, W.; Piekorz, R.P.; Knoefel, W.T.; et al. Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines. PLoS ONE 2013, 8, e59689. [Google Scholar] [CrossRef]
- Kuś, K.; Mark Treherne, J.; Earnshaw, D.L.; Krzykawska, R.; Biesaga, B.; Statkiewicz, M.; Unrug-Bielawska, K.; Sandowska-Markiewicz, Z.; Mikula, M.; Alfaro, J.A.; et al. 3D Culture of Pancreatic Cancer Cells In Vitro Recapitulates an Aberrant Mitochondrial Oxidative Phosphorylation Genotype Observed in Vivo. bioRxiv 2024. [Google Scholar] [CrossRef]
- Lam, H. 3D Co-Culture Spheroid Drug Screening Platform for Pancreatic Cancer Invasion. Ph.D. Thesis, King’s College London, London, UK, 2018. [Google Scholar]
- Papapostolou, I.; Bochen, F.; Peinelt, C.; Maldifassi, M.C. A Simple and Fast Method for the Formation and Downstream Processing of Cancer-Cell-Derived 3D Spheroids: An Example Using Nicotine-Treated A549 Lung Cancer 3D Spheres. Methods Protoc. 2023, 6, 94. [Google Scholar] [CrossRef]
- Iversen, P.W.; Beck, B.; Chen, Y.-F.; Dere, W.; Devanarayan, V.; Eastwood, B.J.; Farmen, M.W.; Iturria, S.J.; Montrose, C.; Moore, R.A.; et al. HTS Assay Validation. In Assay Guidance Manual; Markossian, S., Grossman, A., Baskir, H., Arkin, M., Auld, D., Austin, C., Baell, J., Brimacombe, K., Chung, T.D.Y., Coussens, N.P., et al., Eds.; Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda, MD, USA, 2004. [Google Scholar]
- Campioni, G.; Pasquale, V.; Busti, S.; Ducci, G.; Sacco, E.; Vanoni, M. An Optimized Workflow for the Analysis of Metabolic Fluxes in Cancer Spheroids Using Seahorse Technology. Cells 2022, 11, 866. [Google Scholar] [CrossRef]
- Roper, S.J.; Linke, F.; Scotting, P.J.; Coyle, B. 3D Spheroid Models of Paediatric SHH Medulloblastoma Mimic Tumour Biology, Drug Response and Metastatic Dissemination. Sci. Rep. 2021, 11, 4259. [Google Scholar] [CrossRef] [PubMed]
- Vinci, M.; Gowan, S.; Boxall, F.; Patterson, L.; Zimmermann, M.; Court, W.; Lomas, C.; Mendiola, M.; Hardisson, D.; Eccles, S.A. Advances in Establishment and Analysis of Three-Dimensional Tumor Spheroid-Based Functional Assays for Target Validation and Drug Evaluation. BMC Biol. 2012, 10, 29. [Google Scholar] [CrossRef] [PubMed]
- Rorabacher, D.B. Statistical Treatment for Rejection of Deviant Values: Critical Values of Dixon’s “Q” Parameter and Related Subrange Ratios at the 95% Confidence Level. Anal. Chem. 1991, 63, 139–146. [Google Scholar] [CrossRef]
- Fay, D.S. A Biologist’s Guide to Statistical Thinking and Analysis. WormBook 2013, 1, 1–54. [Google Scholar] [CrossRef] [PubMed]
- Kubiak, R.J.; Zhang, J.; Ren, P.; Yang, H.; Roskos, L.K. Excessive Outlier Removal May Result in Cut Points That Are Not Suitable for Immunogenicity Assessments. J. Immunol. Methods 2018, 463, 105–111. [Google Scholar] [CrossRef]
- Paolini, G.V.; Lyons, R.A.; Laflin, P. How Desirable Are Your IC50s?: A Way to Enhance Screening-Based Decision Making. SLAS Discov. 2010, 15, 1183–1193. [Google Scholar] [CrossRef]
- Eastwood, B.J.; Farmen, M.W.; Iversen, P.W.; Craft, T.J.; Smallwood, J.K.; Garbison, K.E.; Delapp, N.W.; Smith, G.F. The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies. SLAS Discov. 2006, 11, 253–261. [Google Scholar] [CrossRef] [PubMed]
- Barnett, V.; Lewis, T. Outliers in Statistical Data, 3rd ed.; Wiley Series in Probability and Mathematical Statistics; J. Wiley & Sons: New York, NY, USA, 1994; ISBN 978-0-471-93094-5. [Google Scholar]
- CellProfiler Granularity Measurements—Image Analysis. Available online: https://forum.image.sc/t/cellprofiler-granularity-measurements/36966/2 (accessed on 10 May 2025).
- Stirling, D.R.; Swain-Bowden, M.J.; Lucas, A.M.; Carpenter, A.E.; Cimini, B.A.; Goodman, A. CellProfiler 4: Improvements in Speed, Utility and Usability. BMC Bioinform. 2021, 22, 433. [Google Scholar] [CrossRef]
- Pythex: A Python Regular Expression Editor. Available online: https://pythex.org/?regex=Channel%5B1-2%5D-%5B0-9%5D%7B2%7D-(%3FP%3CWellRow%3E%5BA-H%5D)-(%3FP%3CWellColumn%3E%5B0-9%5D%7B2%7D)%5C.tif&test_string=Channel1-01-A-01.tif&ignorecase=0&multiline=0&dotall=0&verbose=0 (accessed on 21 January 2025).
- McDermott, C.; Rossa, C. Data Augmentation Based on Inverse Transform Sampling for Improved Tissue Classification via Electrical Impedance Spectroscopy. In Proceedings of the 2023 IEEE Sensors Applications Symposium (SAS), Ottawa, ON, Canada, 18–20 July 2023; IEEE: Piscataway, NJ, USA, 2023; pp. 1–6. [Google Scholar]
- Smit, D.J.A.; Boersma, M.; Schnack, H.G.; Micheloyannis, S.; Boomsma, D.I.; Hulshoff Pol, H.E.; Stam, C.J.; de Geus, E.J.C. The Brain Matures with Stronger Functional Connectivity and Decreased Randomness of Its Network. PLoS ONE 2012, 7, e36896. [Google Scholar] [CrossRef]
- Cangelosi, R.; Goriely, A. Component Retention in Principal Component Analysis with Application to cDNA Microarray Data. Biol. Direct 2007, 2, 2. [Google Scholar] [CrossRef]
- Jolliffe, I.T. Principal Component Analysis; Springer Series in Statistics; Springer: New York, NY, USA, 2002; ISBN 978-0-387-95442-4. [Google Scholar]
- Costanti, F.; Kola, A.; Scarselli, F.; Valensin, D.; Bianchini, M. A Deep Learning Approach to Analyze NMR Spectra of SH-SY5Y Cells for Alzheimer’s Disease Diagnosis. Mathematics 2023, 11, 2664. [Google Scholar] [CrossRef]
- Yao, F.; Müller, H.-G.; Wang, J.-L. Functional Linear Regression Analysis for Longitudinal Data. Ann. Stat. 2005, 33, 2873–2903. [Google Scholar] [CrossRef]
- Cushion, E.J.; Warmenhoven, J.; North, J.S.; Cleather, D.J. Principal Component Analysis Reveals the Proximal to Distal Pattern in Vertical Jumping Is Governed by Two Functional Degrees of Freedom. Front. Bioeng. Biotechnol. 2019, 7, 193. [Google Scholar] [CrossRef] [PubMed]
- Rodionova, O.; Kucheryavskiy, S.; Pomerantsev, A. Efficient Tools for Principal Component Analysis of Complex Data—A Tutorial. Chemom. Intell. Lab. Syst. 2021, 213, 104304. [Google Scholar] [CrossRef]
- Sun, S.; Zhu, J.; Ma, Y.; Zhou, X. Accuracy, Robustness and Scalability of Dimensionality Reduction Methods for Single-Cell RNA-Seq Analysis. Genome Biol. 2019, 20, 269. [Google Scholar] [CrossRef]
- Tsuyuzaki, K.; Sato, H.; Sato, K.; Nikaido, I. Benchmarking Principal Component Analysis for Large-Scale Single-Cell RNA-Sequencing. Genome Biol. 2020, 21, 9. [Google Scholar] [CrossRef]
- Mittler, F.; Obeïd, P.; Rulina, A.V.; Haguet, V.; Gidrol, X.; Balakirev, M.Y. High-Content Monitoring of Drug Effects in a 3D Spheroid Model. Front. Oncol. 2017, 7, 293. [Google Scholar] [CrossRef]
- Walzl, A.; Unger, C.; Kramer, N.; Unterleuthner, D.; Scherzer, M.; Hengstschläger, M.; Schwanzer-Pfeiffer, D.; Dolznig, H. The Resazurin Reduction Assay Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening Assays. SLAS Discov. 2014, 19, 1047–1059. [Google Scholar] [CrossRef]
- Kroupová, J.; Hanuš, J.; Štěpánek, F. Surprising Efficacy Twist of Two Established Cytostatics Revealed by A-La-Carte 3D Cell Spheroid Preparation Protocol. Eur. J. Pharm. Biopharm. 2022, 180, 224–237. [Google Scholar] [CrossRef]
- Hamilton, G.; Rath, B. Role of Circulating Tumor Cell Spheroids in Drug Resistance. CDR 2019, 2, 762–772. [Google Scholar] [CrossRef]
- Fonseca-Benitez, A.; Casallas, L.H.C.; Guarnizo-Mendez, H.; Perdomo-Lara, S.J. Automatic Tool for Analysis of Morphometric Changes in the Tumor Spheroids Regions Treated with Cisplatin. Res. Sq. 2022. preprint. [Google Scholar]
- Piccinini, F. AnaSP: A Software Suite for Automatic Image Analysis of Multicellular Spheroids. Comput. Methods Programs Biomed. 2015, 119, 43–52. [Google Scholar] [CrossRef] [PubMed]
- Amaral, R.L.F.; Miranda, M.; Marcato, P.D.; Swiech, K. Comparative Analysis of 3D Bladder Tumor Spheroids Obtained by Forced Floating and Hanging Drop Methods for Drug Screening. Front. Physiol. 2017, 8, 605. [Google Scholar] [CrossRef] [PubMed]
- Sundaramoorthy, S.; Colombo, D.F.; Sanalkumar, R.; Broye, L.; Balmas Bourloud, K.; Boulay, G.; Cironi, L.; Stamenkovic, I.; Renella, R.; Kuttler, F.; et al. Preclinical Spheroid Models Identify BMX as a Therapeutic Target for Metastatic MYCN Nonamplified Neuroblastoma. JCI Insight 2024, 9, e169647. [Google Scholar] [CrossRef] [PubMed]
- Minin, A.; Semerikova, T.; Belousova, A.V.; Karavashkova, O.; Pozdina, V.; Tomilina, M.; Zubarev, I. MSLASpheroidStamp: 3d Cell Spheroids for Everyone. Bioprinting 2025, 49, e00416. [Google Scholar] [CrossRef]
- Han, S.J.; Kwon, S.; Kim, K.S. Challenges of Applying Multicellular Tumor Spheroids in Preclinical Phase. Cancer Cell Int. 2021, 21, 152. [Google Scholar] [CrossRef] [PubMed]







| Cell Line | Pathology | Seeding Density (Cells/Well) |
|---|---|---|
| HCT116 | Colorectal Cancer | 500 |
| LoVo | Colorectal Cancer | 100 |
| PANC-1 | Pancreatic Cancer | 1000 |
| CFPAC-1 | Pancreatic Cancer | 1000 |
| Cell Line | Compound | IC50 ± SD, nM (Proliferative) | IC50 ± SD, nM (Metric) | Relation Metric: Proliferative | IC50 ± SD, nM (Area) | Relation Area: Proliferative |
|---|---|---|---|---|---|---|
| HCT116 | Paclitaxel | 0.284 ± 0.05 | 0.33 ± 0.03 | 1.17 | 0.2686 ± 0.05 | 0.95 |
| 5-FU | 921 ± 146 | 1762 ± 264 | 1.91 | 1304 ± 350 | 1.42 | |
| Cytarabine | 303 ± 11.5 | 644 ± 72 | 2.13 | 198.5 ± 10.7 | 0.66 | |
| Niraparib | 3279 ± 1124 | 5300 ± 794 | 1.62 | 1432 ± 42 | 0.44 | |
| Etoposide | >2000 | >2000 | n/a 2 | >2000 | n/a 2 | |
| Oxaliplatin | >10,000 | >2000 | n/a 2 | >2000 | n/a 2 | |
| LoVo | Paclitaxel | n/a 1 | >8 | n/a 2 | 12.9 ± 13.2 | n/a 2 |
| 5-FU | n/a 1 | 0.0014 ± 0.0002 | n/a 2 | 688 ± 253 | n/a 2 | |
| Cytarabine | 14.2 ± 0.4 | 15.2 ± 9.2 | 1.07 | 14.3 ± 0.3 | 1.01 | |
| Niraparib | 270 ± 63 | >400 | >1.5 | 693 ± 10 | 2.57 | |
| Etoposide | n/a 1 | >80 | n/a 2 | 283 ± 14 | n/a 2 | |
| Oxaliplatin | n/a 1 | >80 | n/a 2 | >400 | n/a 2 | |
| PANC-1 | Paclitaxel | 1.24 ± 0.04 | 1.28 ± 0.26 | 1.03 | 1.31 ± 0.60 | 1.06 |
| 5-FU | 1361 ± 150 | >400 | >0.29 | 738 ± 53 | 0.54 | |
| Cytarabine | 254 ± 23.5 | 498 ± 160 | 1.96 | 325 ± 62 | 1.28 | |
| Niraparib | 563 ± 102 | 478 ± 22 | 0.85 | 451 ± 19 | 0.80 | |
| Etoposide | 1982 ± 5 | 1904 ± 154 | 0.96 | 2041 ± 9 | 1.03 | |
| Oxaliplatin | 1705 ± 170 | 457 ± 162 | 0.27 | 1717 ± 189 | 1.01 | |
| CFPAC-1 | Paclitaxel | 0.01 ± 0.01 | 0.012 ± 0.002 | 1.20 | 0.011 ± 0.001 | 1.10 |
| 5-FU | 328 ± 27 | 71.8 ± 18.3 | 0.22 | 286 ± 30 | 0.87 | |
| Cytarabine | 71.0 ± 3.4 | 66.0 ± 35.3 | 0.93 | 43.3 ± 4.2 | 0.61 | |
| Niraparib | >3.2 | >80 | n/a 2 | >80 | n/a 2 | |
| Etoposide | >2000 | >2000 | n/a 2 | >400 | n/a 2 | |
| Oxaliplatin | >10,000 | 527 ± 54 | >0.05 | >400 | n/a 2 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
Trofimov, M.A.; Bulatov, I.P.; Lavrinenko, V.S.; Popov, V.E.; Petrova, V.S.; Bukatin, A.S.; Tyazhelnikov, S.F. Visualization, Data Extraction, and Multiparametric Analysis of 3D Pancreatic and Colorectal Cancer Cell Lines for High-Throughput Screening. Biomedicines 2026, 14, 108. https://doi.org/10.3390/biomedicines14010108
Trofimov MA, Bulatov IP, Lavrinenko VS, Popov VE, Petrova VS, Bukatin AS, Tyazhelnikov SF. Visualization, Data Extraction, and Multiparametric Analysis of 3D Pancreatic and Colorectal Cancer Cell Lines for High-Throughput Screening. Biomedicines. 2026; 14(1):108. https://doi.org/10.3390/biomedicines14010108
Chicago/Turabian StyleTrofimov, Mikhail A., Ilya P. Bulatov, Velemir S. Lavrinenko, Vladimir E. Popov, Varvara S. Petrova, Anton S. Bukatin, and Stanislav F. Tyazhelnikov. 2026. "Visualization, Data Extraction, and Multiparametric Analysis of 3D Pancreatic and Colorectal Cancer Cell Lines for High-Throughput Screening" Biomedicines 14, no. 1: 108. https://doi.org/10.3390/biomedicines14010108
APA StyleTrofimov, M. A., Bulatov, I. P., Lavrinenko, V. S., Popov, V. E., Petrova, V. S., Bukatin, A. S., & Tyazhelnikov, S. F. (2026). Visualization, Data Extraction, and Multiparametric Analysis of 3D Pancreatic and Colorectal Cancer Cell Lines for High-Throughput Screening. Biomedicines, 14(1), 108. https://doi.org/10.3390/biomedicines14010108

